{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:47:29Z","timestamp":1782366449473,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic nephropathy (DN) is a progressive microvascular complication of diabetes and a leading cause of end-stage renal disease, with limited disease-modifying therapeutic options. DN is characterized by progressive renal dysfunction, oxidative stress, inflammation, fibrosis, and activation of inflammasome-related pathways. Silymarin, a natural compound with antioxidant and anti-inflammatory properties, has demonstrated renoprotective potential; however, its association with miRNA-223\/NLRP3\/caspase-1\/GSDMD signaling in DN remains incompletely defined. Therefore, the present study investigated the potential renoprotective effects of silymarin in a high-fat diet\/streptozotocin (HFD\/STZ)-induced rat model of DN, with particular focus on miRNA-223 expression and inflammasome-associated pyroptotic signaling. Diabetic rats received oral silymarin (100\u00a0mg\/kg\/day) either for 12 weeks as an early intervention or 4 weeks as a delayed treatment. Renal function indices, blood glucose, HbA1c, serum insulin, HOMA-IR, LDH, lipid profile, body weight, kidney weight\/body weight index, oxidative stress markers, and histopathological changes were evaluated. Renal expression of miRNA-223, NOD-like receptor family pyrin domain-containing 3 (NLRP3), caspase-1, gasdermin D (GSDMD), nuclear factor-kappa B (NF-\u03baB) (p65), hypoxia-inducible factor-1 alpha (HIF-1\u03b1), tumor necrosis factor-alpha (TNF-\u03b1), interleukin-1 beta (IL-1\u03b2), and fibronectin was assessed using RT-qPCR, ELISA, and immunohistochemistry. Silymarin significantly improved renal function, glycemic control, insulin resistance, lipid profile, oxidative stress, inflammatory mediators, HIF-1\u03b1 expression, LDH activity, histopathological injury, and fibrosis relative to untreated DN rats. Moreover, silymarin was associated with increased renal miRNA-223 expression and reduced expression of NLRP3, caspase-1, and GSDMD. These effects were more pronounced in the early intervention group compared with delayed treatment. In conclusion, silymarin attenuated experimental DN via modulation of the miRNA-223\/NLRP3\/caspase-1\/GSDMD axis and suppression of pyroptosis-associated signaling, alongside improvement of oxidative stress, inflammation, hypoxia, fibrosis, and metabolic disturbances. Further mechanistic studies are warranted to clarify the causal relationship between miRNA-223 modulation and the observed renoprotective effects of silymarin.<\/jats:p>","DOI":"10.1186\/s13062-026-00857-6","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:24:29Z","timestamp":1782289469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Silymarin attenuates diabetic nephropathy in rats via modulation of the miRNA-223\/NLRP3\/caspase-1\/GSDMD axis and inflammasome-related pyroptotic signaling"],"prefix":"10.1186","volume":"21","author":[{"given":"Merna G.","family":"Aboismaiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila A.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"857_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","volume":"2067","author":"MK Sagoo","year":"2020","unstructured":"Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3\u20137.","journal-title":"Methods Mol Biol"},{"key":"857_CR2","doi-asserted-by":"crossref","unstructured":"Wu T, et al. The mechanism of hyperglycemia-induced renal cell injury in diabetic nephropathy disease: an update. Life (Basel). 2023;13(2):539.","DOI":"10.3390\/life13020539"},{"issue":"4","key":"857_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.4093\/dmj.2024.0593","volume":"49","author":"Y Cao","year":"2025","unstructured":"Cao Y, et al. Global, regional, and national temporal trends in incidence for type 2 diabetes mellitus-related chronic kidney disease from 1992 to 2021. Diabetes Metab J. 2025;49(4):848\u201361.","journal-title":"Diabetes Metab J"},{"key":"857_CR4","doi-asserted-by":"publisher","first-page":"1196016","DOI":"10.3389\/fimmu.2023.1196016","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Natural products in attenuating renal inflammation via inhibiting the NLRP3 inflammasome in diabetic kidney disease. Front Immunol. 2023;14:1196016.","journal-title":"Front Immunol"},{"key":"857_CR5","doi-asserted-by":"publisher","first-page":"Article13","DOI":"10.3389\/fphar.2022.998574","volume":"13","author":"J Wan","year":"2022","unstructured":"Wan J, et al. NLRP3-mediated pyroptosis in diabetic nephropathy. Front Pharmacol. 2022;13:Article13.","journal-title":"Front Pharmacol"},{"issue":"7","key":"857_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41419-023-06005-6","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance. Cell Death Dis. 2023;14(7):472.","journal-title":"Cell Death Dis"},{"key":"857_CR7","doi-asserted-by":"publisher","first-page":"8399","DOI":"10.2147\/JIR.S524246","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. NLRP3 inflammasome-mediated pyroptosis in diabetic nephropathy: pathogenic mechanisms and therapeutic targets. J Inflamm Res. 2025;18:8399\u2013418.","journal-title":"J Inflamm Res"},{"issue":"3","key":"857_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"AC Hesp","year":"2020","unstructured":"Hesp AC, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020;98(3):579\u201389.","journal-title":"Kidney Int"},{"issue":"1","key":"857_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40620-024-02152-x","volume":"38","author":"M Kleibert","year":"2025","unstructured":"Kleibert M, et al. The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease. J Nephrol. 2025;38(1):37\u201347.","journal-title":"J Nephrol"},{"key":"857_CR10","doi-asserted-by":"publisher","first-page":"1722159","DOI":"10.3389\/fmed.2025.1722159","volume":"12","author":"S Lin","year":"2025","unstructured":"Lin S, et al. Inflammatory mechanisms in diabetic nephropathy: emerging insights and targeted therapeutics. Front Med (Lausanne). 2025;12:1722159.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"857_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/febs.13578","volume":"283","author":"L D\u2019Ignazio","year":"2016","unstructured":"D\u2019Ignazio L, Bandarra D, Rocha S. NF-\u03baB and HIF crosstalk in immune responses. FEBS J. 2016;283(3):413\u201324.","journal-title":"FEBS J"},{"key":"857_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/ijms27010420","volume":"27","author":"Z Zou","year":"2026","unstructured":"Zou Z, Zhou N, Zhang C. miRNA in the progression of diabetic kidney disease: new insight. Int J Mol Sci. 2026;27:420. https:\/\/doi.org\/10.3390\/ijms27010420.","journal-title":"Int J Mol Sci"},{"key":"857_CR13","doi-asserted-by":"publisher","first-page":"Article16","DOI":"10.3389\/fphar.2025.1713259","volume":"16","author":"D Mannino","year":"2026","unstructured":"Mannino D, et al. Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer. Front Pharmacol. 2026;16:Article16.","journal-title":"Front Pharmacol"},{"key":"857_CR14","doi-asserted-by":"crossref","unstructured":"Speeckaert R, Delrue C, Speeckaert MM. Residual renal risk in diabetic nephropathy despite contemporary therapies. J Clin Med. 2026;15(3).","DOI":"10.3390\/jcm15030921"},{"key":"857_CR15","doi-asserted-by":"publisher","first-page":"1637393","DOI":"10.3389\/fphar.2025.1637393","volume":"16","author":"M Selc","year":"2025","unstructured":"Selc M, Babelova A. Looking beyond silybin: the importance of other silymarin flavonolignans. Front Pharmacol. 2025;16:1637393.","journal-title":"Front Pharmacol"},{"issue":"8","key":"857_CR16","first-page":"e67083","volume":"16","author":"D Dhande","year":"2024","unstructured":"Dhande D, et al. Silymarin as an antioxidant therapy in chronic liver diseases: a comprehensive review. Cureus. 2024;16(8):e67083.","journal-title":"Cureus"},{"key":"857_CR17","doi-asserted-by":"crossref","unstructured":"Georgiev T, et al. Vitamin E and silymarin reduce oxidative tissue damage during gentamicin-induced nephrotoxicity. Pharmaceuticals (Basel). 2023;16(10).","DOI":"10.3390\/ph16101365"},{"key":"857_CR18","doi-asserted-by":"crossref","unstructured":"Sayyad M, et al. Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. Front Pharmacol. 2025;16:Article 16.","DOI":"10.3389\/fphar.2025.1711653"},{"issue":"1","key":"857_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2042-6410-4-12","volume":"4","author":"JL Whitney","year":"2013","unstructured":"Whitney JL, et al. Growth hormone exacerbates diabetic renal damage in male but not female rats. Biol Sex Differ. 2013;4(1):12.","journal-title":"Biol Sex Differ"},{"issue":"18","key":"857_CR20","doi-asserted-by":"publisher","first-page":"e14197","DOI":"10.14814\/phy2.14197","volume":"7","author":"L Tian","year":"2019","unstructured":"Tian L, Nikolic-Paterson DJ, Tesch GH. Establishing equivalent diabetes in male and female Nos3-deficient mice results in a comparable onset of diabetic kidney injury. Physiol Rep. 2019;7(18):e14197.","journal-title":"Physiol Rep"},{"key":"857_CR21","first-page":"274","volume":"22","author":"A Ghasemi","year":"2023","unstructured":"Ghasemi A, Jeddi S. Streptozotocin as a tool for induction of rat models of diabetes: a practical guide. EXCLI J. 2023;22:274\u201394.","journal-title":"EXCLI J"},{"key":"857_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.plefa.2017.06.009","volume":"136","author":"SM Eraky","year":"2018","unstructured":"Eraky SM, Abdel-Rahman N, Eissa LA. Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. Prostaglandins Leukot Essent Fat Acids. 2018;136:123\u20139.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"857_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2016.06.002","volume":"157","author":"YA Samra","year":"2016","unstructured":"Samra YA, et al. Cepharanthine and piperine ameliorate diabetic nephropathy in ratss: role of NF-\u03baB and NLRP3 inflammasome. Life Sci. 2016;157:187\u201399.","journal-title":"Life Sci"},{"key":"857_CR24","doi-asserted-by":"publisher","first-page":"15872","DOI":"10.1038\/s41598-022-20297-2","volume":"12","author":"R Karimi","year":"2022","unstructured":"Karimi R, et al. Silymarin reduces retinal microvascular damage in streptozotocin-induced diabetic rats. Sci Rep. 2022;12:15872.","journal-title":"Sci Rep"},{"issue":"6","key":"857_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"4","key":"857_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/ijerph13040380","volume":"13","author":"AK Patlolla","year":"2016","unstructured":"Patlolla AK, et al. Toxicity evaluation of graphene oxide in kidneys of Sprague-Dawley Rats. Int J Environ Res Public Health. 2016;13(4):380.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"857_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1):248\u201354.","journal-title":"Anal Biochem"},{"key":"857_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","volume":"1180","author":"AT Feldman","year":"2014","unstructured":"Feldman AT, Wolfe D. Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 2014;1180:31\u201343.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"857_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0021-9975(05)80087-8","volume":"112","author":"J Yamate","year":"1995","unstructured":"Yamate J, et al. Immunohistochemical observations on the kinetics of macrophages and myofibroblasts in rat renal interstitial fibrosis induced by cis-diamminedichloroplatinum. J Comp Pathol. 1995;112(1):27\u201339.","journal-title":"J Comp Pathol"},{"key":"857_CR30","doi-asserted-by":"crossref","unstructured":"Alvi MM, et al. Post-treatment of synthetic polyphenolic 1,3,4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration. Biomolecules. 2020;10(6).","DOI":"10.3390\/biom10060816"},{"issue":"2","key":"857_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21608\/kvmj.2020.40514.1010","volume":"18","author":"F Zakzook","year":"2020","unstructured":"Zakzook F, et al. Thymoquinone attenuates dimethoate induced hepatic and testicular genotoxicity in rats. Kafrelsheikh Vet Med J. 2020;18(2):25\u201332.","journal-title":"Kafrelsheikh Vet Med J"},{"key":"857_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40659-024-00527-9","volume":"57","author":"MG Aboismaiel","year":"2024","unstructured":"Aboismaiel MG, Amin NM, Eissa LA. Renoprotective effect of a novel combination of 6-gingerol and metformin in high-fat diet\/streptozotocin-induced diabetic nephropathy in rats via targeting miRNA-146a, miRNA-223, TLR4\/TRAF6\/NLRP3 inflammasome pathway and HIF-1\u03b1. Biol Res. 2024;57:47.","journal-title":"Biol Res"},{"issue":"1","key":"857_CR33","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/s41598-017-02320-z","volume":"7","author":"M Matboli","year":"2017","unstructured":"Matboli M, et al. Caffeic Acid Attenuates Diabetic Kidney Disease via Modulation of Autophagy in a High-Fat Diet\/Streptozotocin- Induced Diabetic Rat. Sci Rep. 2017;7(1):2263.","journal-title":"Sci Rep"},{"key":"857_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/life13020539","volume":"13","author":"T Wu","year":"2023","unstructured":"Wu T, et al. The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. Life. 2023;13:539. https:\/\/doi.org\/10.3390\/life13020539.","journal-title":"Life"},{"key":"857_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4103\/jpbs.jpbs_497_21","volume":"13","author":"S Aziz","year":"2022","unstructured":"Aziz S, et al. Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic. Nephropathy? J Pharm Bioallied Sci. 2022;13:341.","journal-title":"Nephropathy? J Pharm Bioallied Sci"},{"issue":"4","key":"857_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.phrs.2005.05.004","volume":"52","author":"K Srinivasan","year":"2005","unstructured":"Srinivasan K, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313\u201320.","journal-title":"Pharmacol Res"},{"issue":"4","key":"857_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/S0102-865020150040000007","volume":"30","author":"T Bazzano","year":"2015","unstructured":"Bazzano T, et al. Renal biomarkers of male and female Wistar rats (Rattus norvegicus) undergoing renal ischemia and reperfusion. Acta Cir Bras. 2015;30(4):277\u201388.","journal-title":"Acta Cir Bras"},{"key":"857_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cbi.2018.02.001","volume":"284","author":"HO Abou-Hany","year":"2018","unstructured":"Abou-Hany HO, et al. Crocin mediated amelioration of oxidative burden and inflammatory cascade suppresses diabetic nephropathy progression in diabetic rats. Chem Biol Interact. 2018;284:90\u2013100.","journal-title":"Chem Biol Interact"},{"key":"857_CR39","doi-asserted-by":"publisher","first-page":"119197","DOI":"10.1016\/j.lfs.2021.119197","volume":"271","author":"Y Chen","year":"2021","unstructured":"Chen Y, Chen L, Yang T. Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-\u03b2\/Smad and JAK2\/STAT3\/SOCS1 pathway. Life Sci. 2021;271:119197.","journal-title":"Life Sci"},{"key":"857_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/DDDT.S294009","volume":"15","author":"L Guo","year":"2021","unstructured":"Guo L, et al. Nephroprotective Effect of Adropinin Against Streptozotocin-Induced Diabetic Nephropathy in Rats: Inflammatory Mechanism and YAP\/TAZ Factor. Drug Des Devel Ther. 2021;15:589\u2013600.","journal-title":"Drug Des Devel Ther"},{"key":"857_CR41","doi-asserted-by":"publisher","first-page":"ArticleID","DOI":"10.1155\/2016\/3853242","volume":"2016","author":"X Li","year":"2016","unstructured":"Li X, et al. Involvement of histone lysine methylation in p21 gene expression in rat kidney in vivo and rat mesangial cells in vitro under diabetic conditions. J Diabetes Res. 2016;2016:ArticleID.","journal-title":"J Diabetes Res"},{"issue":"1","key":"857_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cbin.11079","volume":"43","author":"S Meng","year":"2019","unstructured":"Meng S, et al. Silymarin ameliorates diabetic cardiomyopathy via inhibiting TGF-\u03b21\/Smad signaling. Cell Biol Int. 2019;43(1):65\u201372.","journal-title":"Cell Biol Int"},{"key":"857_CR43","doi-asserted-by":"crossref","unstructured":"MacDonald-Ramos K, et al. Silymarin reduced insulin resistance in non-diabetic women with obesity. Int J Mol Sci. 2024;25(4).","DOI":"10.3390\/ijms25042050"},{"key":"857_CR44","first-page":"493","volume":"15","author":"A Amniattalab","year":"2016","unstructured":"Amniattalab A, et al. Silymarin: A Novel Natural Agent to Restore Defective Pancreatic \u03b2 Cells in Streptozotocin (STZ)-induced Diabetic Rats. Iran J Pharm Res. 2016;15:493\u2013500.","journal-title":"Iran J Pharm Res"},{"key":"857_CR45","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.2147\/DDDT.S305033","volume":"15","author":"X Zhao","year":"2021","unstructured":"Zhao X, et al. Protective Effects of Silymarin Against D-Gal\/LPS-Induced Organ Damage and Inflammation in Mice. Drug Des Devel Ther. 2021;15:1903\u201314.","journal-title":"Drug Des Devel Ther"},{"key":"857_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.biopha.2018.09.042","volume":"108","author":"AM Stolf","year":"2018","unstructured":"Stolf AM, et al. Effects of silymarin on angiogenesis and oxidative stress in streptozotocin-induced diabetes in mice. Biomed Pharmacother. 2018;108:232\u201343.","journal-title":"Biomed Pharmacother"},{"key":"857_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy. Signal Transduct Target Ther. 2022;7:216.","journal-title":"Signal Transduct Target Ther"},{"key":"857_CR48","doi-asserted-by":"crossref","unstructured":"Mashnafi S, et al. Effects of diet-induced weight loss on plasma markers for cholesterol absorption and synthesis: secondary analysis of a randomized trial in abdominally obese men. Nutrients. 2022;14(8).","DOI":"10.3390\/nu14081546"},{"issue":"1","key":"857_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12\u201322.","journal-title":"J Clin Invest"},{"key":"857_CR50","doi-asserted-by":"publisher","first-page":"821209","DOI":"10.3389\/fnut.2022.821209","volume":"9","author":"A Lecamwasam","year":"2022","unstructured":"Lecamwasam A, et al. Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk. Front Nutr. 2022;9:821209.","journal-title":"Front Nutr"},{"issue":"19","key":"857_CR51","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.2217\/nnm-2016-0204","volume":"11","author":"YM El-Far","year":"2016","unstructured":"El-Far YM, et al. A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes. Nanomed (Lond). 2016;11(19):2581\u2013602.","journal-title":"Nanomed (Lond)"},{"key":"857_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phymed.2018.03.050","volume":"44","author":"S Ebrahimpour-Koujan","year":"2018","unstructured":"Ebrahimpour-Koujan S, et al. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial. Phytomedicine. 2018;44:39\u201344.","journal-title":"Phytomedicine"},{"key":"857_CR53","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/nu9091006","volume":"9","author":"V Marin","year":"2017","unstructured":"Marin V, et al. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients. 2017;9:1006.","journal-title":"Nutrients"},{"key":"857_CR54","doi-asserted-by":"publisher","first-page":"113821","DOI":"10.1016\/j.intimp.2024.113821","volume":"146","author":"Y Liao","year":"2025","unstructured":"Liao Y, et al. Unraveling the priming phase of NLRP3 inflammasome activation: Molecular insights and clinical relevance. Int Immunopharmacol. 2025;146:113821.","journal-title":"Int Immunopharmacol"},{"key":"857_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduction and Targeted Therapy. Signal Transduct Target Ther. 2023;8:152.","journal-title":"Signal Transduct Target Ther"},{"key":"857_CR56","doi-asserted-by":"crossref","unstructured":"Sahakyan G, et al. The role of oxidative stress-mediated inflammation in the development of T2DM-induced diabetic nephropathy: possible preventive action of tannins and other oligomeric polyphenols. Molecules. 2022;27(24).","DOI":"10.3390\/molecules27249035"},{"issue":"12","key":"857_CR57","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/ph17121568","volume":"17","author":"S Shamas","year":"2024","unstructured":"Shamas S, et al. Pyroptosis in Endothelial Cells and Extracellular Vesicle Release in Atherosclerosis via NF-\u03baB-Caspase-4\/5-GSDM-D Pathway. Pharmaceuticals. 2024;17(12):1568.","journal-title":"Pharmaceuticals"},{"issue":"11","key":"857_CR58","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00210-021-02163-6","volume":"394","author":"S Houshmandfar","year":"2021","unstructured":"Houshmandfar S, et al. miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(11):2187\u201395.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"857_CR59","doi-asserted-by":"publisher","first-page":"907504","DOI":"10.3389\/fphys.2022.907504","volume":"13","author":"BM Williams","year":"2022","unstructured":"Williams BM, et al. The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy. Front Physiol. 2022;13:907504.","journal-title":"Front Physiol"},{"issue":"9","key":"857_CR60","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.7150\/ijbs.59876","volume":"17","author":"P Jiao","year":"2021","unstructured":"Jiao P, et al. An Effective Regulator of Immune Cell Differentiation and Inflammation. Int J Biol Sci. 2021;17(9):2308\u201322.","journal-title":"Int J Biol Sci"},{"key":"857_CR61","doi-asserted-by":"publisher","first-page":"117980","DOI":"10.1016\/j.lfs.2020.117980","volume":"256","author":"D Xu","year":"2020","unstructured":"Xu D, et al. Inhibition of miR-223 attenuates the NLRP3 inflammasome activation, fibrosis, and apoptosis in diabetic cardiomyopathy. Life Sci. 2020;256:117980.","journal-title":"Life Sci"},{"key":"857_CR62","doi-asserted-by":"publisher","first-page":"109808","DOI":"10.1016\/j.intimp.2023.109808","volume":"116","author":"S Tang","year":"2023","unstructured":"Tang S, et al. The novel hepatoprotective mechanisms of silibinin-phospholipid complex against d-GalN\/LPS-induced acute liver injury. Int Immunopharmacol. 2023;116:109808.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"857_CR63","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1002\/fsn3.4010","volume":"12","author":"HM Jaffar","year":"2024","unstructured":"Jaffar HM, et al. Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review. Food Sci Nutr. 2024;12(5):3097\u2013111.","journal-title":"Food Sci Nutr"},{"key":"857_CR64","doi-asserted-by":"crossref","unstructured":"Jin Q, et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1185317"},{"key":"857_CR65","doi-asserted-by":"crossref","unstructured":"Awad AM, et al. Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-\u03baB, NLRP3 inflammasome, and autophagy pathways. Inflammopharmacology. 2023.","DOI":"10.1007\/s10787-023-01301-1"},{"key":"857_CR66","first-page":"1","volume":"2022","author":"W Mi","year":"2022","unstructured":"Mi W, et al. Analysis of the Renal Protection and Antioxidative Stress Effects of Panax notoginseng Saponins in Diabetic Nephropathy Mice. J Immunol Res. 2022;2022:1\u20139.","journal-title":"J Immunol Res"},{"issue":"9","key":"857_CR67","first-page":"690","volume":"33","author":"LMO Miranda","year":"2020","unstructured":"Miranda LMO, et al. Silymarin Attenuates Hepatic and Pancreatic Redox Imbalance Independent of Glycemic Regulation in the Alloxan-induced Diabetic Rat Model. Biomed Environ Sci. 2020;33(9):690\u2013700.","journal-title":"Biomed Environ Sci"},{"key":"857_CR68","doi-asserted-by":"crossref","unstructured":"Stanigut AM, et al. Hypoxia-inducible factors and diabetic kidney disease-how deep can we go? Int J Mol Sci. 2022;23(18).","DOI":"10.3390\/ijms231810413"},{"key":"857_CR69","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2337\/db15-0519","volume":"65","author":"BK Nayak","year":"2016","unstructured":"Nayak BK, et al. HIF-1 mediates renal fibrosis in OVE26 Type 1 diabetic mice. Diabetes. 2016;65:1387\u201397.","journal-title":"Diabetes"},{"key":"857_CR70","doi-asserted-by":"publisher","first-page":"6114132","DOI":"10.1155\/2021\/6114132","volume":"2021","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xu R, Wang Z. Contribution of Oxidative Stress to HIF-1-Mediated Profibrotic Changes during the Kidney Damage. Oxid Med Cell Longev. 2021;2021:6114132.","journal-title":"Oxid Med Cell Longev"},{"key":"857_CR71","doi-asserted-by":"publisher","first-page":"e22477","DOI":"10.1096\/fj.202200845R","volume":"36","author":"S Mei","year":"2022","unstructured":"Mei S, et al. Susceptibility of renal fibrosis in diabetes: Role of hypoxia inducible factor-1. FASEB J. 2022;36:e22477.","journal-title":"FASEB J"},{"key":"857_CR72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/DDDT.S224308","volume":"14","author":"R Liu","year":"2020","unstructured":"Liu R, et al. Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-\u03b21 Signaling in Kidney. Drug Des Devel Ther. 2020;14:603\u201311.","journal-title":"Drug Des Devel Ther"},{"key":"857_CR73","doi-asserted-by":"publisher","first-page":"1729941","DOI":"10.3389\/fphar.2025.1729941","volume":"16","author":"J Gong","year":"2025","unstructured":"Gong J, et al. Molecular mechanisms and multi-target therapeutic strategies of diabetic nephropathy: from pathogenesis to precision interventions. Front Pharmacol. 2025;16:1729941.","journal-title":"Front Pharmacol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00857-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00857-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00857-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:16:20Z","timestamp":1782364580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00857-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00857-6","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}